Spasms, Infantile
4
0
1
1
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
11 treatments under study, led by Nitrazepam
Research Leaders
6 sponsors active, led by National Institute of Neurological Disorders and Stroke (NINDS)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
25.0%
1 terminated out of 4 trials
50.0%
-36.6% vs benchmark
50%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Clinical Trial on 7-day Followed by Maintenance Therapy for 10 Weeks vs. 14-day and no Maintenance Course of Prednisolone for the Treatment of Infantile Epileptic Spasms Syndrome (IESS)
A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms
Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms
Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment
Research Network
Common Treatments
- Nitrazepam1
- Valproic Acid1
- Adrenocorticotropic Hormone1
- Carbamazepine1
- Vigabatrin1
Active Sponsors
- National Institute of Neurological Disorders and Stroke (NINDS)1
- Amzell1
- University of California, Los Angeles1
- INSYS Therapeutics Inc1
- University of Colombo1
Top Investigators
INSYS Therapeutics Inc
University of California, Los Angeles
Department of Paediatrics at the Faculty of Medicine, University of Colombo, Sri Lanka
Department of Community Medicine, Faculty of Medicine, University of Colombo, Sri Lanka
Department of Paediatrics, University of Sri Jayewardenepura, Sri Lanka
Related Conditions
- Epilepsy1
- Prednisolone1